Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Wuhan Keqian Biology Co.,Ltd (688526.SS)
CNY13.09
+0.23 (+1.79%)
CN SHH Healthcare Biotechnology
Address
No. 419, Gaoxin 2nd Road 430073
Wuhan, ZJ, CN
Wuhan, ZJ, CN
CEO
Mu Lin Chen
Website
kqbio.com
IPO
2019-07-22
ISIN CNE1000042Q8
Description
Wuhan Keqian Biology Co.,Ltd focuses on the research and development, production, sales, and animal epidemic prevention technical services of veterinary biological products in China. The company offers vaccines for pigs, poultry, and pets, as well as diagnostic reagents. Wuhan Keqian Biology Co.,Ltd was founded in 2001 and is based in Wuhan, China.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
CNY13.09
+0.23 (+1.79%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
2M
Beta
0.44
Float Shares
115.48M
Free Float %
24.8%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.84% | -7.26% | -8.74% | -21.54% | -16.61% | -13.83% | -22.87% | -43.68% | -67.56% | -58.36% | -58.36% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
13.09
DCF (Unlevered)
9.89
-24.5%
DCF (Levered)
7.89
-39.7%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
9.27
Safe zone
Piotroski F-Score
6 / 9
Average
MOAT Score
6 / 10
Developing
Composite Rating
A
Overall Score
4 / 5
High
DCF Score
4 / 5
High
ROE Score
4 / 5
High
ROA Score
5 / 5
High
D/E Score
4 / 5
High
P/E Score
2 / 5
Medium
P/Book Score
3 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%+0.9% Q1'26: -7.2% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%+9.8% Q1'26: -26.1% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%+44.5% ★ Q1'26: +22.0% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%+50.2% ★ Q1'26: +39.6% (vs Q1'25)
-
ROIC Biotechnology: -16.1%+16.5% ★ Q1'26: +12.9% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%-1.0% ★ Q1'26: -1.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×0.01× ★ Q1'26: 0.01× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 2 Rev. Ana. 4 EPS Ana. |
Dec 2027 3 Rev. Ana. 4 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|
| Revenue |
843.23M
est: 845.20M (-0.2%)
|
1.10B
est: 1.10B (+0.0%)
|
1.00B
est: 1.07B (-6.2%)
|
1.06B
est: 932.75M (+14.1%)
|
941.92M
est: 1.01B (-6.5%)
|
950.29M
est: 1.19B (-20.3%)
|
1.05B
971.06M – 1.14B
-11.7% YoY
|
1.16B
1.05B – 1.35B
+10.3% YoY
|
1.32B
1.29B – 1.35B
+13.4% YoY
|
| EBITDA |
557.46M
est: 430.96M (+29.4%)
|
724.50M
est: 562.16M (+28.9%)
|
569.00M
est: 544.22M (+4.6%)
|
578.98M
est: 554.05M (+4.5%)
|
551.13M
est: 598.11M (-7.9%)
|
585.07M
est: 708.60M (-17.4%)
|
625.55M
576.81M – 674.29M
-11.7% YoY
|
689.98M
621.40M – 801.15M
+10.3% YoY
|
782.30M
765.37M – 799.23M
+13.4% YoY
|
| EBIT |
520.43M
est: 360.16M (+44.5%)
|
661.86M
est: 469.80M (+40.9%)
|
472.05M
est: 454.81M (+3.8%)
|
465.74M
est: 462.86M (+0.6%)
|
442.90M
est: 499.67M (-11.4%)
|
476.84M
est: 591.97M (-19.4%)
|
522.59M
481.88M – 563.31M
-11.7% YoY
|
576.41M
519.12M – 669.29M
+10.3% YoY
|
653.55M
639.40M – 667.69M
+13.4% YoY
|
| Net Income |
447.80M
est: 435.51M (+2.8%)
|
570.74M
est: 572.36M (-0.3%)
|
409.52M
est: 454.16M (-9.8%)
|
395.93M
est: 309.38M (+28.0%)
|
382.35M
est: 365.61M (+4.6%)
|
415.60M
est: 389.72M (+6.6%)
|
429.00M
377.08M – 502.77M
+10.1% YoY
|
519.82M
414.14M – 579.79M
+21.2% YoY
|
571.00M
499.19M – 655.04M
+9.8% YoY
|
| SGA |
153.06M
est: 162.91M (-6.0%)
|
201.91M
est: 212.51M (-5.0%)
|
219.26M
est: 205.73M (+6.6%)
|
213.20M
est: 158.50M (+34.5%)
|
169.40M
est: 171.10M (-1.0%)
|
64.05M
est: 202.71M (-68.4%)
|
178.95M
165.01M – 192.90M
-11.7% YoY
|
197.38M
177.77M – 229.19M
+10.3% YoY
|
223.80M
218.95M – 228.64M
+13.4% YoY
|
| EPS |
1.16
est: 0.93 (+24.2%)
|
1.23
est: 1.23 (+0.2%)
|
0.88
est: 0.97 (-9.7%)
|
0.85
est: 0.67 (+27.1%)
|
0.82
est: 0.78 (+5.8%)
|
0.90
est: 0.94 (-3.7%)
|
0.93
0.82 – 1.09
-0.5% YoY
|
1.07
0.90 – 1.26
+14.5% YoY
|
1.22
1.08 – 1.42
+14.9% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | A | 4/5 | 4/5 | 4/5 | 5/5 | 4/5 | 2/5 | 3/5 |
| 2026-05-28 | A | 4/5 | 4/5 | 4/5 | 5/5 | 4/5 | 2/5 | 3/5 |
| 2026-05-27 | A- | 4/5 | 3/5 | 4/5 | 5/5 | 4/5 | 2/5 | 3/5 |
| 2026-05-26 | A- | 4/5 | 3/5 | 4/5 | 5/5 | 4/5 | 2/5 | 3/5 |
| 2026-05-25 | A- | 4/5 | 3/5 | 4/5 | 5/5 | 4/5 | 2/5 | 3/5 |
| 2026-05-22 | A- | 4/5 | 3/5 | 4/5 | 5/5 | 4/5 | 2/5 | 3/5 |
| 2026-05-21 | A- | 4/5 | 3/5 | 4/5 | 5/5 | 4/5 | 2/5 | 3/5 |
| 2026-05-20 | A- | 4/5 | 3/5 | 4/5 | 5/5 | 4/5 | 2/5 | 3/5 |
| 2026-05-19 | A- | 4/5 | 3/5 | 4/5 | 5/5 | 4/5 | 2/5 | 3/5 |
| 2026-05-18 | A- | 4/5 | 3/5 | 4/5 | 5/5 | 4/5 | 2/5 | 3/5 |
| 2026-05-15 | A | 4/5 | 3/5 | 4/5 | 5/5 | 4/5 | 2/5 | 4/5 |
| 2026-05-14 | A | 4/5 | 3/5 | 4/5 | 5/5 | 4/5 | 2/5 | 4/5 |
| 2026-05-13 | A | 4/5 | 3/5 | 4/5 | 5/5 | 4/5 | 3/5 | 4/5 |
| 2026-05-12 | A | 4/5 | 3/5 | 4/5 | 5/5 | 4/5 | 3/5 | 4/5 |
| 2026-05-11 | A | 4/5 | 3/5 | 4/5 | 5/5 | 4/5 | 3/5 | 4/5 |
| 2026-05-08 | A | 4/5 | 4/5 | 3/5 | 5/5 | 4/5 | 3/5 | 4/5 |
| 2026-05-07 | A | 4/5 | 4/5 | 3/5 | 5/5 | 4/5 | 3/5 | 4/5 |
| 2026-05-06 | A | 4/5 | 4/5 | 3/5 | 5/5 | 4/5 | 3/5 | 4/5 |
| 2026-04-30 | A | 4/5 | 4/5 | 3/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-04-29 | A | 4/5 | 4/5 | 3/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-04-28 | A | 4/5 | 4/5 | 3/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-04-27 | A | 4/5 | 4/5 | 3/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-04-24 | A | 4/5 | 4/5 | 3/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-04-23 | A | 4/5 | 4/5 | 3/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-04-22 | A | 4/5 | 4/5 | 3/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-04-21 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-20 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-17 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-16 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
183.57M
OE per share TTM
0.40
Owner's Yield
2.99%
Maintenance CapEx ratio
156.41%
Maint CapEx / Avg PPE
70.8%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
Held by 13 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Vanguard FTSE All-World ex-US Small-Cap ETF VSS | 0.00% | 187.7K | 0.06% |
| 2 | Vanguard FTSE Emerging Markets Shares ETF VGE.AX | 0.00% | 5.5K | 0.48% |
| 3 | Vanguard FTSE Emerging Markets All Cap Index ETF VEE.TO | 0.00% | 12.4K | 0.26% |
| 4 | Vanguard FTSE Emerging Markets ETF VWO | 0.00% | 610.8K | 0.06% |
| 5 | Vanguard ESG International Stock ETF VSGX | 0.00% | 7.1K | 0.10% |
| 6 | Vanguard Total International Stock ETF VXUS | 0.00% | 679.0K | 0.05% |
| 7 | Vanguard FTSE Global All Cap ex Canada Index ETF VXC.TO | 0.00% | 981.54 | 0.22% |
| 8 | Vanguard All-Equity ETF Portfolio VEQT.TO | 0.00% | 3.0K | 0.22% |
| 9 | Vanguard Growth ETF Portfolio VGRO.TO | 0.00% | 1.6K | 0.22% |
| 10 | Vanguard Balanced ETF Portfolio VBAL.TO | 0.00% | 700.29 | 0.22% |
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
501.9K
Shares Outstanding
466.13M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Chan Cha Chen | Accounting Supervisor | — | — |
| Deng Hong | Deputy General Manager | — | male |
| Gaoyuan Xu | Executive Deputy General Manager | — | male |
| Guanping Chen | Deputy General Manager | — | male |
| Ming Zhong | Chief Financial Officer, Deputy GM & Vice Chairman | — | male |
| Mulin Chen | GM & Chairman | — | female |
| Tiantian Zou | Board Secretary | — | female |
| Xibiao Tang | Deputy General Manager | — | male |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 688526.SS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
